Clinical Trials

Home » Clinical Trials
Click here to go to clinicaltrials.gov


View Tips and Talking Points for Supporting a Patient’s Decision
to Enroll in a Clinical Trial Here


Featured Clinical Trials

New Data vs Bicalutamide

Indication XTANDI (enzalutamide) capsules is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Important Safety Information Contraindications  XTANDI is not indicated for women. XTANDI can cause fetal harm and potential loss of pregnancy. Warnings and Precautions Seizure occurred in 0.5% of patients receiving XTANDI in clinical studies. In placebo-controlled studies, 8 of 1671...

AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

  AbbVie and Bristol-Myers Squibb Company  announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC). The Phase 1/2...

Current Ariad Clinical Trials

Ponatinib OPTIC– A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses OPTIC-2L– A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib Phase 1/2 study of ponatinib...

New Gynecologic Oncology Clinical Trials Sylvester Comp Cancer Center Sylvester Comp Cancer Center

The Sylvester Comprehensive Cancer Center’s Division of Gynecologic Oncology’s Research Program is opening 4 new clinical trials for women with ovarian, cervical and endometrial cancer. These include two surgical trials evaluating the role of sentinel lymph node biopsy in cervical and endometrial cancer and two immunotherapy trials in first-line and recurrent ovarian cancer. They continue...

Who’s Online

There are no users currently online